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Background: Studies have evaluated the concomitant use of hyaluronan (HA) with steroids, anti-inflammatory
drugs and analgesic agents in an attempt to magnify the extent and duration of pain relief due to knee osteoarthritis. To
date there has not been an intra-articular combination therapy available for relief of knee osteoarthritis symptoms – one
that combines the fast acting onset of symptom relief provided by a corticosteroid with the long-lasting symptom relief
provided by HA in a single injection. The objective of this study was to evaluate the safety and preliminary performance
of two new HA formulations, Hydros (hyaluronan-based hydrogel suspended in hyaluronan solution) and
Hydros-TA (HA plus 10 mg of triamcinolone acetonide [TA]) in subjects with knee osteoarthritis.
Methods: We conducted a Phase 2 prospective, multicenter, randomized, double-blind feasibility trial.
Participants (n = 98; mean age 60 years) with knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) were randomized to
three treatment groups: Hydros, Hydros-TA, and Synvisc-One® (hylan G-F 20). Participants received one 6 ml
intra-articular injection in the treatment knee and were evaluated at 2, 6, 13, and 26 weeks post-treatment.
Safety was assessed from adverse events at all study visits. The primary efficacy outcome was the change
from baseline on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A (Pain) score
for the treatment knee.
Results: Adverse events were similar across treatment groups with the most common being arthralgia, joint
swelling, back pain, and joint stiffness. Arthralgia was reported 5 times with Synvisc-One, 4 with Hydros, and
1 with Hydros-TA. Each group demonstrated a reduction in the WOMAC A (Pain) score over 26 weeks:
[least-square mean (standard error)] 30.5 (5.1) mm for Hydros; 34.4 (4.7) mm for Hydros-TA; 28.0 (5.4) mm for
Synvisc-One and an observed improvement of 2.5 mm (p= 0.64) and 6.4 mm (p= 0.24) over Synvisc-One for Hydros and
Hydros-TA, respectively.
Conclusions: A single injection of Hydros or Hydros-TA was well-tolerated and relieved pain associated with knee
osteoarthritis over 26 weeks. Data indicate that Hydros-TA had a more rapid pain relief compared to Hydros alone.
A Phase 3 trial is underway to confirm these preliminary results.
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Osteoarthritis (OA) is a common degenerative joint dis-
ease that is characterized by loss of articular cartilage,
subchondral bone sclerosis, osteophyte formation, changes
in the synovial membrane, and reduced viscosity of syn-
ovial fluid [1]. OA is the leading cause of disability in
high-income countries. On a global scale, OA is consid-
ered to be the fifth leading cause of Years Lost to Disabil-
ity (YLD) in high-income countries, according to a World
Health Organization (WHO) report [2]. Pain from OA has
a major influence on a patient’s quality of life and carries a
heavy economic burden.
There are several non-surgical options for treating
pain associated with OA, ranging from measures that
limit weight impact on the joints, to oral analgesics and
anti-inflammatory drugs, to intra-articular (IA) steroid
and viscosupplement injections [3].
HA is a linear polymer of repeating disaccharide
units (each composed of D-glucuronic acid and D-N-
acetylglucosamine, linked together via glycosidic bonds)
and is found in significant concentration in the synovial
fluid and articular cartilage of joints [4]. HA is respon-
sible for the viscoelastic properties of synovial fluid and
has been shown to be chondroprotective in experimen-
tal studies [5,6]. IA injections of HA are used for visco-
supplementation of osteoarthritic joints to improve the
viscoelastic properties of synovial fluid and relieve pain.
In a meta-analysis of 54 randomized controlled trials,
HA injections showed a therapeutic effect at 4 weeks
post-injection which peaked at 8 weeks and extended
over 6 months [7].
Viscosupplementation with HA is a common IA ther-
apy that is effective in relieving knee pain caused by OA.
However, viscosupplements typically have a delayed on-
set of pain relief, with little effect observed for the first
2 weeks following injection. A review by Bellamy et al.
[8] involving 76 randomized, controlled trials confirmed
that viscosupplements did not reach peak effectiveness
until 5 weeks post-injection.
TA is a well-known synthetic corticosteroid, approved
for IA injection, and is indicated as adjunctive therapy
for short-term administration for acute episodes or exac-
erbations of OA. It is known from the literature that TA
can directly inhibit the activation of inflammatory cells
and their release of degradation products and recruit-
ment factors [9]. A meta-analysis of 10 randomized con-
trolled trials concluded that evidence supports short-
term (up to two weeks) improvement in symptoms of
knee OA after IA corticosteroid injection [10], and re-
peated use of IA corticosteroid injections has been found
to be safe and clinically effective when given every three
months over a period of two years [11].
TA is a well-known, well-studied synthetic corticoster-
oid that also has a long history of safe use for IAinjection, having been on the US market for over
50 years. As different formulations, it is administered by
injection, orally, by inhalation, and topically. It was first
approved by the FDA in 1960. Corticosteroids are com-
mon IA therapies, and doses ranging from 10–40 mg
have been demonstrated to be safe and effective for IA
injection. In contrast to viscosupplements, corticoste-
roids have a very fast onset of pain relief but the effect is
short-term, lasting 2 to 3 weeks. A Cochrane review
which included 28 trials and 1,973 participants con-
cluded that IA steroids were effective for 2 to 3 weeks
post injection, but that there was a lack of evidence of
effect on pain and function at 4 to 24 weeks post-
injection [12]. Bannuru et al., had similar findings [13].
Studies have evaluated the concomitant use of HA
with steroids, anti-inflammatory drugs, and analgesic
agents (although they were not co-formulated) in an at-
tempt to magnify the extent and duration of pain relief.
In a one-year study of HA with and without TA, both
groups improved, with the combination-therapy subjects
improving sooner [14]. In addition, next to a fast-acting
onset of symptom relief, corticosteroids may reduce the
number of post-injection flares. Other clinical studies
have successfully used steroids with HA for pain relief
and consider this combination treatment as complemen-
tary therapy [15,16]. To date there has not been an IA
combination therapy (co-formulated) available for relief
of knee OA symptoms – one that combines the fast act-
ing onset of symptom relief provided by a corticosteroid
with the long-lasting symptom relief provided by HA in
a single IA injection.
The purpose of this study was to evaluate the safety
and preliminary performance of two new formulations,
one HA product (Hydros) and one HA product that also
contained a low-dose corticosteroid (Hydros-TA) in sub-
jects with knee OA. These products were compared to
Synvisc-One, a viscosupplement currently manufactured
and distributed by Genzyme (a Sanofi company).Methods
Materials
A new viscosupplement formulation, containing a bios-
resorbable HA-based hydrogel suspended in a HA solu-
tion, (Hydros), was developed to provide long-term relief
from OA pain in a single IA injection. The hydrogel
component is manufactured by crosslinking bacteria-
derived, modified HA polymer with a polyethylene glycol
crosslinker. A unique feature of Hydros is the ability to
entrap a low-dose corticosteroid, in this case TA, into
the hydrogel component. The addition of a corticoster-
oid (Hydros-TA) was designed to provide more rapid
pain relief to the long lasting pain relief of Hydros alone.
A single dose Hydros-TA contained 10 mg of TA.
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compared to a control viscosupplement, Synvisc-One
(hylan G-F 20), manufactured by Genzyme.
Study population
Subjects were included in the study if they had knee OA
of grades 2 or 3 on the Kellgren-Lawrence [17] grading
system (confirmed radiologically), were ambulatory, and
were between the ages 40 to 80 years old. Additionally, all
subjects were required to have a WOMAC A (Pain) score
averaging 50-90 mm in the treatment knee, using a visual
analog scale (VAS) that ranged from 0-100 mm [18].
Subjects were excluded if they had: a WOMAC A
(Pain) score >30 mm in the non-treated knee; IA steroid
injections within the previous 3 months of the screening
visit; IA HA injections within the 6 months prior to the
screening visit; secondary OA or general symptomatic
OA of lower extremity; hypersensitivity to avian pro-
teins, corticosteroids, or HA-based products; active in-
fection in either knee joint; uncontrolled diabetes; or a
body mass index over 35.
All enrolled subjects had to agree to restrict pain
medication to a maximum of 4 grams of paracetamol for
knee pain (all other pain medication was excluded with
the exception of NSAIDS for up to three days for non-
treatment knee pain). No pain medication was allowed
within 48 hours of a study visit.
Study design
This Phase 2 trial was a prospective, multicenter, ran-
domized, double-blind, feasibility study to evaluate the
safety and performance of Hydros and Hydros-TA in
subjects with knee OA (see Table 1 for participating cen-
ters). Subjects were equally randomized into one of three
treatment groups and received a one-time 6 mL injec-
tion of Hydros, Hydros-TA, or Synvisc-One. Subjects
were seen for post-injection follow-up assessment at 2,
6, 13, and 26 weeks.
Subjects and evaluating physicians, who followed sub-
jects post-treatment, were blinded to treatment. AnTable 1 Participating centers, Principal Investigators and num
Investigational site
Lawson Health Research Institute Ontario, Canada
Women's College Hospital Toronto, Canada
The University of British Columbia (UBC) Vancouver, Canada
Sentro di Speshalista Spectrum Willemstad, Curacao
Research Orhopedie UZ Leuven, Belgium
Care to Move St. Niklaas, Belgium
University Hospital Maastricht Maastricht, The Netherlands
St. Anna Ziekenhuis Hospital Geldrop, The Netherlands
Eight (8) Enrolled Centersinjecting physician delivered the randomized treatment
and remained unblinded. All randomized subjects re-
ceived one IA injection in the treatment knee by an
injecting physician. The treatment knee was the knee
that met the inclusion criteria on the WOMAC A (Pain)
score and received one of the three IA injection treat-
ments, as determined by sequential randomization at
each study site. The randomization treatment was com-
puter generated and was stratified by study center.
The study was performed in strict adherence to the
protocol and in accord with the Declaration of Helsinki,
the applicable guidelines for good clinical practices, ISO
14155, Clinical Investigation of Medical Devices for Hu-
man Subjects, mandates of the Ethics Committees, and
all applicable national and local laws and regulations. In
addition, appropriate training and support in the use of
the investigational product were provided. Investigators
were responsible for enrolling into the study only those
subjects who conformed to the inclusion criteria and for
whom no exclusion criteria applied (study registered
with ClinicalTrials.gov; NCT 01134406). Institutional re-
view board and/or ethics committee review and approval
was sought and obtained by each individual site. For ex-
ample, at the largest site, approval was obtained from
Western University’s Health Sciences Research Ethics
Board. All subjects provided written informed consent.
Safety evaluations
Assessments of all adverse events (AEs) for all study
visits were performed by the blinded evaluating phys-
ician. Any AE reported post-treatment was considered a
Treatment-Emergent Adverse Event (TEAE) and were
summarized by treatment group, using a Medical Dic-
tionary for Regulatory Activities (MedDRA) version 13.1
preferred terms, system organ classifications, and sever-
ity. If a subject experienced multiple events that mapped
to a single preferred term, the greatest severity grade and
strongest investigator assessment of relation to study
medication was assigned to the preferred term for the ap-
propriate summaries. For subjects who experienced theber of subjects treated
Principal investigator Total Pt.
Robert Petrella, MD 39
Julia Alleyne, MD 10
Don McKenzie, MD 1
E. de Windt, MD 23
Johan Bellemans, MD 2
Frank Dellaert, MD 11
Pieter Emans, MD 11
H. J. Hoekstra, MD 1
Total: 98
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presented. AEs were assessed for relation to treatment
and procedure.
Primary efficacy assessment
The change from baseline in WOMAC A (Pain) score
for knee pain covering the 48-hour period prior to the
follow-up visit for all follow-up visits was measured for
each subject.
Secondary efficacy assessments
Changes in WOMAC B (Stiffness) and WOMAC C
(Function) scores from baseline were evaluated similarly
to the Pain score. Global assessments by the subjects at
13 weeks and subject and physician global assessments
at 26 weeks were obtained. OMERACT-OARSI guide-
lines [19] were used to define the number and percent-
age of positive “strict responders” (≥50% and ≥20 mm
improvements in WOMAC A (Pain) or C (Function)
scores over baseline). Average weekly consumption of
paracetamol in grams over the 26-week post-treatment
period was captured.
Statistical analyses
A sample size of 90 subjects (30 subjects per group) was
intended to provide 1) preliminary information on the
safety and tolerability of Hydros and Hydros-TA and 2)Figure 1 COR 1.0 randomization and follow-up.a preliminary review of efficacy of these two modalities
as compared to the control, Synvisc-One. Intent-to-
Treat (ITT) methodology (all randomized subjects) was
used to analyze subjects by treatment group for efficacy
and safety. For the primary efficacy endpoint, Least
Square Means from a repeated measure ANCOVA
model with effects for study center, treatment, visit, visit
by treatment interaction, and baseline subscale value
were utilized to assess difference between treatment
groups. The Cochran-Mantel Haenszel General Associ-
ation statistic, stratified by study center, was used to assess
differences among treatments and to assess differences in
the pairwise comparisons between treatments in the
OMERACT-OARSI response rate. Rounding for all nu-
merical values occurred only as the last step for all results
presented.
Results
Participant flow and characteristics
Ninety-eight subjects out of 158 subjects screened met
the eligibility criteria and were randomly assigned to one
of three treatment groups (see Figure 1).
Demographics and OA knee baseline characteristics
were similar between all groups (Table 2). The average
subject age was 60 (range 40–84 years) and 43% were
male. The Hydros group had the largest female to male







Age in years, mean (SD) 59 (12) 61 (11) 59 (12)
Gender, n (%)
Male 12 (38) 14 (41) 16 (50)
Female 20 (63) 20 (59) 16 (50)
Race, n (%)
Caucasian 23 (72) 28 (82) 23 (72)
Non-Caucasian 9 (28) 6 (18) 9 (28)
Body Mass Index in kg/m2, mean (SD) 29.8 (4.1) 29.0 (4.1) 29.0 (3.8)
Kellgren-Lawrence Grade for Treatment Knee, n (%)
Grade 2 18 (56) 22 (65) 18 (56)
Grade 3 14 (44) 12 (35) 14 (44)
Pre-Treatment WOMAC score in mm, mean (SD)
Treatment Knee 68 (9) 69 (11) 66 (12)
Non-treatment Knee 13 (8) 12 (9) 12 (8)
Duration of Symptoms - Pre-Treatment in Treatment
Knee in months, mean (SD)
64 (59) 74 (80) 69 (56)
Abbreviations: WOMAC =Western Ontario and McMaster Universities Osteoarthritis Index.
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groups, and 76% of subjects were Caucasian.Adverse events
A total of 7 subjects reported Serious Adverse Events
(SAEs). In the Hydros group, the 3 reported SAEs were
colitis, broncho-pneumonia and arthralgia. In the Hydros-
TA group, the 2 reported SAEs included a report of a
meniscal lesion and a cyst aspiration. Lastly, the two SAEs
reported in the Synvisc-One group were a meniscal lesionTable 3 Number of adverse events reported in ≥ 5% of subjec
AE description Synvisc-One n = 32
Any TEAE, n (%) 23 (72)
Arthralgia, n (%) 8 (25)
Joint Swelling, n (%) 2 (6)
Joint Stiffness, n (%) 2 (6)
Back Pain, n (%) 3 (9)
Muscle Spasms, n (%) 1 (3)
Arthritis, n (%) 0
Headache, n (%) 8 (25)
Nasopharyngitis, n (%) 3 (9)
Nausea, n (%) 1 (3)
Meniscus Lesion, n (%) 1 (3)
Tendon Pain, n (%) 2 (6)
Abbreviations: AE = Adverse Event; TEAE = Treatment-Emergent Adverse Event.and an elective surgery. All SAEs were considered unlikely
or definitely not related to treatment and had resolved by
the termination of the study.
Treatment Emergent Adverse Events (TEAEs) were re-
ported in 69% of all subjects treated. The most com-
monly reported TEAEs were arthralgia, joint swelling,
joint stiffness and back pain. Table 3 lists the AEs by
treatment group, which occurred in 5% or more of the
overall ITT population.
AEs for 15 subjects were reported as “Likely” or “Def-
initely” related to study treatment: 6 in the Synvisc-Onets by treatment group
Hydros n = 32 Hydros-TA n = 34
24 (75) 21 (62)
11 (34) 7 (21)
3 (9) 2 (6)
3 (9) 0
1 (3) 1 (3)
0 3 (9)
2 (6) 0
6 (19) 4 (12)
1 (3) 1 (3)
2 (6) 1 (3)
0 2 (6)
0 0
Table 4 Adverse events "likely" or "definitely" related to study treatment







Tissue disorders, n (%)
Arthralgia 5 (16) 4 (13) 1 (3)
Joint Stiffness 2 (6) 2 (6) 0
Joint Swelling 1 (3) 0 0
General Disorders and Administration
Site conditions, n (%)
Application Site Warmth 1 (3) 0 0
Injection Site Warmth 0 0 1 (3)
Injection Site Movement Impairment 0 1 (3) 0
Injection site pain 0 0 1 (3)
Total Related Adverse Events,n (%) NA 9 (28) 7 (22) 3 (9)
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There were a total of 19 AEs related to study treatment in
these 15 subjects: 9 in the Synvisc-One group, 7 in the Hydros
group, and 3 in the Hydros-TA group. The most commonly
reported AEs related to study treatment were arthralgia and
joint stiffness. These results are summarized in Table 4.Table 5 Mean reduction on WOMAC A (Pain), B (Stiffness), an
Mean reduction (Pain) from Baseline [LSMeans(SE)]
Time Points Synvisc-One n=32 Hydros n=32 Hydros-TA
Baseline 66.4 68.1 69.4
2 weeks -28.5 (5.9) -23.3 (5.6) -35.6 (5.2)
6 weeks -25.6 (5.9) -32.4 (5.6) -33.4 (5.2)
13 weeks -29.0 (6.0) -33.9 (5.6) -33.3 (5.2)
26 weeks -28.9 (6.0) -32.4 (5.6) -35.2 (5.3)
Overall -28.0 (5.4) -30.5 (5.1) -34.4 (4.7)
Mean reduction (Stiffness) from Baseline [LSMeans(SE)
Time Points Synvisc-One n=32 Hydros n=32 Hydros-TA
Baseline 70.1 70.5 70.3
2 weeks -25.9 (6.7) -18.4 (6.4) -33.7 (6.0)
6 weeks -24.0 (6.7) -24.2 (6.4) -31.4 (6.0)
13 weeks -25.9 (6.8) -26.4 (6.4) -27.4 (6.0)
26 weeks -24.6 (6.9) -29.0 (6.5) -26.8 (6.0)
Overall -25.1 (6.1) -24.5 (5.8) -29.8 (5.3)
Mean reduction (Function) from Baseline [LSMeans(SE)
Time Points Synvisc-One n=32 Hydros n=32 Hydros-TA
Baseline 63.5 66.2 65.1
2 weeks -23.7 (6.0) -20.2 (5.8) -32.1 (5.3)
6 weeks -23.5 (6.0) -29.2 (5.8) -29.0 (5.3)
13 weeks -25.6 (6.1) -31.0 (5.8) -29.1 (5.3)
26 weeks -24.5 (6.1) -29.0 (5.8) -29.5 (5.4)
Overall -24.3 (5.6) -27.3 (5.4) -30.0 (4.9)
*For the intent-to-treat population in the Synvisc-One, Hydros, and Hydros TA grou
Abbreviations: WOMAC =Western Ontario and McMaster Universities OsteoarthritisPrimary endpoint: WOMAC a (pain) score (ITT) population
For the WOMAC A (Pain) score change from baseline,
the mean reductions from baseline over 26 weeks
[Least-Square Means (LSMean) Standard Errors (SE)]
were 30.5 (5.1) mm for Hydros, 34.4 (4.7) mm for
Hydros-TA, and 28.0 (5.4) mm for Synvisc-One. Thesed C (Function) scores (mm)*
Between Group Differences
Synvisc-One – Hydros Synvis-One – Hydros-TA
n=34 LSMeans p-value LSMeans p-value
N/A N/A N/A N/A
5.2 0.40 -7.1 0.25
-6.8 0.28 -7.8 0.21
-4.9 0.43 -4.3 0.49
-3.5 0.58 -6.3 0.33
-2.5 0.64 -6.4 0.24
Between Group Differences
] Synvisc-One – Hydros Synvis-One – Hydros-TA
n=34 LSMeans p-value LSMeans p-value
N/A N/A N/A N/A
7.5 0.29 -7.8 0.27
-0.2 0.98 -7.4 0.30
-0.5 0.94 -1.5 0.83
-4.4 0.55 -2.2 0.77
0.6 0.92 -4.7 0.43
Between Group Differences
] Synvisc-One – Hydros Synvis-One – Hydros-TA
n=34 LSMeans p-value LSMeans p-value
N/A N/A N/A N/A
3.5 0.58 -8.4 0.18
-5.7 0.37 -5.5 0.38
-5.4 0.39 -3.5 0.58
-4.5 0.49 -5.0 0.44
-3.0 0.59 -5.6 0.31
ps, observed at landmark time points.
Index; LSMeans = Least Squares Means; SE = Standard Error.
Table 6 Hydros-TA vs. Hydros: Observed mean reduction in WOMAC A (Pain) score*
Time point Hydros n = 32 Hydros-TA n = 34 Difference p-value




Baseline 68.1 69.4 NA NA
2 weeks −23.3 (5.6) −35.6 (5.2) −12.4 0.04
6 weeks −32.4 (5.6) −33.4 (5.2) −1.1 0.86
13 weeks −33.9 (5.6) −33.3 (5.2) 0.6 0.93
26 weeks −32.4 (5.6) −35.2 (5.3) −2.8 0.65
Overall −30.5 (5.1) −34.4 (4.7) −3.9 0.45
*For intent-to-treat population observed at landmark time points.
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(Pain) score for the ITT population for all three treat-
ment groups at each post-treatment follow-up visit are
shown in Table 5. Overall, Hydros and Hydros-TA mean
reductions represent and observed improvement over
Synvisc-One of 2.5 mm (p = 0.64) and 6.4 mm (p = 0.24),
respectively.Secondary endpoint: WOMAC B (stiffness) score
The mean changes in WOMAC B (Stiffness) score from
baseline for the ITT population for each treatment
group are 24.5 (5.8) mm for Hydros, 29.8 (5.3) mm for
Hydros-TA, and 25.1 (6.1) mm for Synvisc-One. The
complete mean reduction data for the WOMAC B (Stiff-
ness) score are reported in Table 5.Secondary endpoint: WOMAC C (function) score
Hydros, Hydros-TA, and Synvisc-One had reductions of
27.3 (5.4) mm, 30.0 (4.9) mm, and 24.3 (5.6) mm, re-
spectively, for the changes from baseline of the overall
mean WOMAC C (Function) score. The complete re-
sults for mean reduction of WOMAC C (Function)
score in the ITT population are shown in Table 5.
In addition, a comparison of the pain reduction pro-
vided by Hydros-TA versus Hydros is presented in Table 6.
While there was not a statistically significant difference
between Hydros-TA and Hydros over 26 weeks, there was
a 12.4 mm improvement in pain scores at the 2 week time
point for Hydros-TA vs. Hydros (p = 0.04). These results
confirm the earlier onset of pain relief for the steroid con-
taining therapy (Hydros-TA) versus the non-steroid con-
taining therapy (Hydros).Table 7 Strict OMERACT-OARSI responder analysis
Group 13 Weeks n (%) 26 Weeks n (%)
Synvisc-One 17 (53) 19 (59)
Hydros 21 (66) 22 (69)
Hydros-TA 24 (71) 22 (65)Secondary endpoint: strict OMERACT-OARSI responder
analysis
The percentages of strict OMERACT-OARSI responders
for Hydros and Hydros-TA were numerically higher than
the strict responders for Synvisc-One at 13 and 26 weeks
(see Table 7).Discussion
This study demonstrated the preliminary safety and toler-
ability of two new formulations, Hydros and Hydros-TA,
for the treatment of knee OA. Additionally, the results of
the WOMAC A (Pain) and WOMAC C (Function) scores,
for both the Hydros and Hydros-TA, and the WOMAC B
(Stiffness) score for Hydros-TA showed the potential for
improved outcomes when compared to Synvisc-One over
the 26 weeks studied. As anticipated in this pilot feasibility
study and due to the small sample size, the improvements
following treatment with Hydros and Hydros-TA were not
statistically significantly different from improvements with
Synvisc-One, but the observed pain reduction with
Hydros-TA was consistently greater than with Synvisc-
One. Furthermore, the trend seen in the observed pain re-
duction in Hydros-TA compared to an active comparator
(Synvisc-One) was approximately 10% from baseline and
provides compelling evidence to move forward with a
more confirmatory Phase 3 trial.
To our knowledge, this is the first Phase 2 randomized
trial to report on the safety and preliminary efficacy of a
single-injection viscosupplement that combines HA and
corticosteroid for the treatment of knee OA. Reductions
in WOMAC A (Pain) scores observed in this study sug-
gest that this combination may have a faster onset of
pain relief compared to non-steroid containing products
and may provide improved pain relief over the full
26 weeks following injection. These results demonstrate
the possible synergistic effect of combining HA with a
corticosteroid. Ozturk et al. [14] in a similar patient
population demonstrated faster and better pain relief
when 2 injections of TA were added to a 6-injection HA
protocol. Grecomoro et al. [16] also showed better pain
relief in knee OA patients at earlier time points when a
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Both of these studies support the observations of the
present study.
Hydros-TA is a proprietary formulation that enables
the delivery of a corticosteroid that is physically trapped
within the viscosupplement. The results obtained with
Hydros-TA described above suggest that combining cor-
ticosteroids and HA in a single injection provides more
rapid and sustained pain relief.
All three treatments were well tolerated. The total
number of AEs among treatment groups was very simi-
lar; however, the numbers of AEs considered by the
treatment-blinded evaluating physicians to be ‘likely’ or
‘definitely’ related to the study treatment were higher in
the Synvisc-One and the Hydros groups, as compared to
the Hydros-TA group. In addition, the percentage of
subjects who responded favorably to the product (as
measured by the OMERACT-OARSI responder rate)
was higher in Hydros and Hydros-TA groups as com-
pared to Synvisc-One.
Inferences related to this study are limited by the small
number of subjects in each group. However, the trends
of improved pain relief observed at all time points in the
Hydros-TA arm compared to Synvisc-One arm indicate
that future Phase 3 trials are warranted to evaluate the
effects of Hydros with the addition of corticosteroids for
patients with knee OA.
Conclusions
The present study demonstrated that a single injection
of Hydros or Hydros-TA was well-tolerated and relieved
pain associated with knee OA over 26 weeks. The study
endpoints indicate that Hydros-TA provides enhanced
pain relief compared to Synvisc-One. Of particular note,
the data from this study suggest that Hydros-TA had a
more rapid pain relief compared to the hyaluronic acid
formulations alone. A Phase 3 trial is currently underway
to confirm these preliminary results.
Competing interests
RP, PE, JA, FD and DG declare that they have no competing interests. MM is
an employee of the study sponsor, Carbylan Therapeutics.
Authors’ contributions
RP contributed to study design, data collection, data analysis and
interpretation, and manuscript preparation. PE contributed to the collection
of data and preparation of the manuscript. JA contributed to the collection
of data and preparation of the manuscript. FD contributed to the collection
of data and preparation of the manuscript. DG contributed to data analysis
and interpretation and manuscript preparation. MM contributed to study
design, study management, data analysis and interpretation, and manuscript
preparation. All authors read and approved the final manuscript.
Authors’ information
Work should be attributed to: Lawson Health Research Institute, Ontario
(Petrella), Women's College Hospital, Toronto (Alleyne), Maastricht University,
Maastricht (Emans), Care to Move, St. Niklaas (Dellaert), Curacao (Morales,
Booi), St. Anna Hospital, Geldrop (Hoekstra), University of Leuven, Leuven
(Bellemans), University of British Columbia, Vancouver (McKenzie).Acknowledgements
The authors would like to thank Jenna Elder of PharPoint Research who
contributed to the design and statistical analyses.
Author details
1Aging, Rehabilitation & Geriatric Care Research Centre, Lawson Health
Research Institute & Departments of Family Medicine, Kinesiology and
Cardiology, Western University, London, Canada. 2Department of
Orthopaedic Surgery, Maastricht University Medical Center, Maastricht, the
Netherlands. 3Department of Family and Community Medicine, University of
Toronto & Sport CARE, Women’s College Hospital, Toronto, Canada. 4Care to
Move, St. Niklaas, Belgium. 5Aging, Rehabilitation & Geriatric Care Research
Centre, Lawson Health Research Institute & Department of Family Medicine
and School of Health Studies, Western University, London, Canada. 6Carbylan
Therapeutics, Palo Alto, USA. 7Department of Epidemiology, University of
Washington, Seattle, USA.
Received: 7 October 2014 Accepted: 27 February 2015References
1. Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv
Drug Deliv Rev. 2006;58:226–42.
2. World Health Organization. The global burden of disease: 2004 update. In:
Department of health statistics and informatics in the information. Geneva:
Evidence and Research Cluster of WHO; 2008.
3. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al.
OARSI recommendations for the management of hip and kneeosteoarthritis,
part I: critical appraisal of existing treatment guidelines and systematic
review of current research evidence. Osteoarthritis Cartilage. 2007;15:981–1000.
4. Schante C, Zuber G, Herlin C, Vandamme T. Chemical modifications of
hyaluronic acid for the synthesis of derivatives for a broad range of
biomedical applications. Carbohydr Polym. 2011;85:469–89.
5. Miyakoshi N, Kobayashi M, Nozaka K, Okada K, Shimada Y, Itoi E. Effects of
intraarticular administration of basic fobroblast growth factor with
hyaluronic acid on osteochondral defects of the knee in rabbits. Arch
Orthop Trauma Surg. 2005;125(10):683–92.
6. Ghosh P, Read R, Numata Y, Smith S, Armstrong S, Wilson D. The effects of
intraarticular administration of hyaluronan in a model of early osteoarthritis
in sheep: II. Cartilage composition and proteoglycan metabolism. Semin
Arthritis Rheum. 1993;22(6 Suppl 1):31–42.
7. Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic
trajectory following intra-articular hyaluronic acid injection in knee
osteoarthritis – meta-analysis. Osteoarthritis Cartilage.
2011;19(6):611–9.
8. Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA.
Viscosupplementation for the treatment of osteoarthritis of the knee.
Cochrane Database Syst Rev. 2006;2:CD005321.
9. Creamer P. Intra-articular corticosteroid injections in osteoarthritis: do they
work and if so, how? Ann Rheum Dis. 1997;56:634–6.
10. Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the
knee: meta-analysis. Br Med J. 2004;328:869.
11. Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier
J, et al. Safety and efficacy of long-term intraarticular steroid injections in
osteoarthritis of the knee: a randomized, double-blind, placebo-controlled
trial. Arthritis Rheum. 2003;48:370–7.
12. Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA. Intraarticular
corticosteroid for treatment of osteoarthritis of the knee. Cochrane
Database Syst Rev. 2006;2:CD005328.
13. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE.
Therapeutic trajectory of hyaluronic acid versus corticosteroids in the
treatment of knee osteorarthritis: a systematic review and meta-analysis.
Arthritis Rheum. 2009;61(12):1704–11.
14. Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R. The safety and efficacy of
intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis:
1-year, single-blind, randomized study. Rheumatol Int. 2006;26:314–9.
15. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin
Rheumatol. 2001;15:609–26.
16. Grecomoro G, Piccione F, Letizia G. Therapeutic synergism between
hyaluronic acid and dexamethasone in the intra-articular treatment of
Petrella et al. BMC Musculoskeletal Disorders  (2015) 16:57 Page 9 of 9osteoarthritis of the knee: a preliminary open study. Curr Med Res Opin.
1992;13:49–55.
17. Kellgren JH, Lawrence JS. Radiographic assessment of osteo-arthritis. Ann
Rheum Dis. 1957;16(4):494–502.
18. Bellamy N. WOMAC® Osteoarthritis Index. User Guide IX 2009.
19. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M,
et al. OMERACT-OARSI initiative: osteoarthritis research society international
set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis
Cartilage. 2004;12(5):389–99.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
